---
document_datetime: 2025-02-06 09:51:33
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/eurneffy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: eurneffy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.5182195
conversion_datetime: 2025-12-17 07:47:04.20984
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## EURneffy

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| T/0003               | Transfer of Marketing Authorisation                                                                   | 07/01/2025                          | 03/02/2025                                  | SmPC, Labelling and PL           |           |
| IB/0002/G            | This was an application for a group of variations. C.I.12 - Inclusion or deletion of black symbol and | 11/12/2024                          | 03/02/2025                                  | SmPC, Labelling and PL           |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | list of medicinal products that are subject to additional monitoring C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   |            |            |      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| IB/0001 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                            | 21/10/2024 | 03/02/2025 | SmPC |